TLR4 antibody (FITC)

Catalog No. ABIN1106220

Product Details anti-TLR4 Antibody (FITC)

Target: TLR4 (Toll-Like Receptor 4 (TLR4))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TLR4 antibody is conjugated to FITC

Application: Flow Cytometry (FACS)

Cross-Reactivity (Details): Species reactivity (tested):Human

Purification: Protein G

Immunogen: TLR4/MD-2 expressing CHO cells/ chimeric TLR4/MD-2 fusion protein

Clone: 7-00E-003

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.1 mg/mL

Buffer: PBS, 0.02 % sodium azide, 1 % bovine serum albumin

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store at 2 - 8 °C.

Target Details for TLR4

Target: TLR4 (Toll-Like Receptor 4 (TLR4))

Alternative Name: CD284 / TLR4 (TLR4 Products)

Background: TLRs belong to a family of proteins that specifically recognizes and senses microbial products. They are highly conserved throughout evolution and act as innate immune recognition receptors against many pathogens. TLR4 is a functional receptor for gram-negative bacterial lipopolysaccharides (LPS). TLR4 associates with MD-2 which is absolutely required for LPS-induced activation of TLR4.MD-2 exists as a cell surface protein in association with TLR4. It also exists as secreted forms consisting of MD-2 monomers and multimers (sMD-2). Circulating sMD-2 is mainly present as a doublet of ~20 and 25 kD, representing differentially glycosylated forms. Unlike TLR4, sMD-2 binds directly LPS without the need of soluble CD14 (sCD14). However, LPS-MD-2 interactions are increased when LPS is pretreated with CD14. Only monomeric sMD-2 is biologically active and able to associate with TLR4 and LPS. sMD-2 circulates in plasma of healthy individuals as a non-active, polymeric protein. In septic plasma, the total amount of sMD-2 was strongly elevated and contained both sMD-2 polymers and monomers. Soluble MD-2 is proposed to be an important mediator of organ inflammation during sepsis. During experimental human endotoxemia, the monomeric and total sMD-2 content in plasma increased with the kinetics of an acute phase protein. This parallels enhanced TLR4 costimulatory activity. In vitro studies revealed that sMD-2 release appears to be restricted to endothelial and dendritic cells.Synonyms: Toll-like receptor 4

NCBI Accession: NM_138554

UniProt: O00206

Pathways: TLR Signaling, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Toll-Like Receptors Cascades, Inflammasome, S100 Proteins